pediatrx inc. phys pharma llc a. pedx owns certain rights to granisol™, ( granisetron hci ), an oral solution used in cancer care to treat nausea and vomiting associated with cancer treatment ( “ granisol ” ) ; b. apricus biosciences, inc. ( “ apricus ” ) owns certain rights to granisol obtained pursuant to a co - promotion agreement between apricus and pedx dated february 21, 2012 ; c. each of pedx and apricus have expressed an interest in bundling their respective interests in granisol for the limited purpose of marketing and selling granisol to a single purchaser ; d. the company, which is engaged in the business of providing business development advisory and consulting services to life sciences companies, is aware of and has access to certain persons that might be interested in purchasing an interest in granisol ; and e. pedx and the company desire to enter into a relationship on the terms and conditions set forth in this agreement. 1. services ( a ) during the term ( as hereinafter defined ) of this agreement, the company shall provide the following services ( the “ services ” ) to pedx : ( i ) from time - to - time during the term of this agreement, the company shall provide to pedx a written list ( the “ list ” ) of select biopharmaceutical companies which the company believes might have an interest in acquiring granisol ( collectively, “ prospective purchasers ” ). ( ii ) from the list, pedx and the company shall collaborate in the selection of prospective purchasers to be contacted by the company and the company shall assist pedx in marketing and selling granisol to those selected prospective purchasers, including arranging for an introduction and the initiation of dialogue with those prospective purchasers. ( iii ) on an as - needed, as - requested basis, the company shall assist pedx in negotiating and documenting the sale of any interest in granisol to a prospective purchaser. ( iv ) the company shall provide written status reports to pedx on a bi - weekly basis ( or such other period as the parties may agree ), detailing any contacts, discussions, etc., with prospective purchasers, in such form as pedx may require, acting reasonably. ( v ) if and to the extent that pedx is